Rittal Mehta

Rittal Mehta

Auto-generated profile, based on publicly available information

Rittal Mehta

Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2019 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
LWLu Wu
Lu Wu
Diamantis I. TsilimigrasDiamantis I. Tsilimigras
Diamantis I. Tsilimigras
APAnghela Z. Paredes
Anghela Z. Paredes
RMRittal Mehta
Rittal Mehta
JHJ. Madison Hyer
J. Madison Hyer
Tim PawlikTim Pawlik
Tim Pawlik

14 February 2020 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
Diamantis I. TsilimigrasDiamantis I. Tsilimigras
Diamantis I. Tsilimigras
DMD. Moris
D. Moris
JHJ. M. Hyer
J. M. Hyer
FBF. Bagante
F. Bagante
KSK. Sahara
K. Sahara
Tim PawlikTim Pawlik
Tim Pawlik
Background Although the Barcelona Clinic Liver Cancer (BCLC) staging system has been largely adopted in clinical practice, recent studies have emphasized the need for further refinement and subclassification of this system. Methods Patients who underwent hepatectomy with curative intent for BCLC‐0, ‐A or ‐B hepatocellular carcinoma (HCC) between 2000 and 2017 were identified using a multi‐institutional database. The tumour burden score (TBS) was calculated, and overall survival (OS) was examined in relation to TBS and BCLC stage. Results Among 1053 patients, 63 (6·0 per cent) had BCLC‐0, 826 (78·4 per cent) BCLC‐A and 164 (15·6 per cent) had BCLC‐B HCC. OS worsened incrementally with higher TBS (5‐year OS 77·9, 61 and 39 per cent for low, medium and high TBS respectively; P < 0·001). No differences in OS were noted among patients with similar TBS, irrespective of BCLC stage (61·6 versus 58·9 per cent for BCLC‐A/medium TBS versus BCLC‐B/medium TBS, P = 0·930; 45 versus 13 per cent for BCLC‐A/high TBS versus BCLC‐B/high TBS, P = 0·175). Patients with BCLC‐B HCC and a medium TBS had better OS than those with BCLC‐A disease and a high TBS (58·9 versus 45 per cent; P = 0·005). On multivariable analysis, TBS remained associated with OS among patients with BCLC‐A (medium TBS: hazard ratio (HR) 2·07, 95 per cent c.i. 1·42 to 3·02, P < 0·001; high TBS: HR 4·05, 2·40 to 6·82, P < 0·001) and BCLC‐B (high TBS: HR 3·85, 2·03 to 7·30; P < 0·001) HCC. TBS could also stratify prognosis among patients in an external validation cohort (5‐year OS 79, 51·2 and 28 per cent for low, medium and high TBS respectively; P = 0·010). Conclusion The prognosis of patients with HCC varied according to the BCLC stage but was largely dependent on the TBS.

13 April 2020 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
DTDiamantis I. Tsilimigras
Diamantis I. Tsilimigras
FBFabio Bagante
Fabio Bagante
DMDimitrios Moris
Dimitrios Moris
JHJ. Madison Hyer
J. Madison Hyer
KSKota Sahara
Kota Sahara
Tim PawlikTim Pawlik
Tim Pawlik

1 January 2020 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
KMKatiuscha Merath
Katiuscha Merath
JHJ. Madison Hyer
J. Madison Hyer
RMRittal Mehta
Rittal Mehta
AFAyesha Farooq
Ayesha Farooq
FBFabio Bagante
Fabio Bagante
Tim PawlikTim Pawlik
Tim Pawlik

9 May 2020 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
DTDiamantis I. Tsilimigras
Diamantis I. Tsilimigras
KSKota Sahara
Kota Sahara
DMDimitrios Moris
Dimitrios Moris
RMRittal Mehta
Rittal Mehta
APAnghela Z. Paredes
Anghela Z. Paredes
Tim PawlikTim Pawlik
Tim Pawlik

20 March 2020 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
AMAmika Moro
Amika Moro
RMRittal Mehta
Rittal Mehta
KSKota Sahara
Kota Sahara
DTDiamantis I. Tsilimigras
Diamantis I. Tsilimigras
APAnghela Z. Paredes
Anghela Z. Paredes
Tim PawlikTim Pawlik
Tim Pawlik